Evidence map›Paper›PMID 34010323›Full record

ArticlePloS one2021

Increasing salinity of fibrinogen solvent generates stable fibrin hydrogels for cell delivery or tissue engineering.

Dillon K Jarrell, Ethan J Vanderslice, Mallory L Lennon, Anne C Lyons, Mitchell C VeDepo, Jeffrey G Jacot

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. AnMaterials today. Communications · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Hydrogels: Properties and Applications in Biomedicine.Molecules (Basel, Switzerland) · 2022
    Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Dillon K JarrellDepartment of Bioengineering, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.ORCID 0000-0002-7299-0870
Ethan J VandersliceDepartment of Bioengineering, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.ORCID 0000-0002-6273-921X
Mallory L LennonDepartment of Bioengineering, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.
Anne C LyonsDepartment of Bioengineering, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.
Mitchell C VeDepoDepartment of Bioengineering, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.ORCID 0000-0001-6584-2792
Jeffrey G JacotDepartment of Bioengineering, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.ORCID 0000-0002-1272-5055
University of Colorado Anschutz Medical Campus · USChildren's Hospital Colorado · US

Funding

Cardiovascular Biomechanics and Imaging in Down SyndromeT32HL072738 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SHANDAS, ROBIN · 2003 to 2025
$4.9M
PRE-VASCULARIZED AND DEGRADABLE PATCHES FOR CORRECTION OF CONGENITAL HEART DEFECTSR01HL130436 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI JACOT, JEFFREY G · 2016 to 2020
$2.0M
NHLBI NIH HHS R01 HL130436NHLBI NIH HHS T32 HL072738
6 · The paper itself

Abstract

Fibrin has been used clinically for wound coverings, surgical glues, and cell delivery because of its affordability, cytocompatibility, and ability to modulate angiogenesis and inflammation. However, its rapid degradation rate has limited its usefulness as a scaffold for 3D cell culture and tissue engineering. Previous studies have sought to slow the degradation rate of fibrin with the addition of proteolysis inhibitors or synthetic crosslinkers that require multiple functionalization or polymerization steps. These strategies are difficult to implement in vivo and introduce increased complexity, both of which hinder the use of fibrin in research and medicine. Previously, we demonstrated that additional crosslinking of fibrin gels using bifunctionalized poly(ethylene glycol)-n-hydroxysuccinimide (PEG-NHS) slows the degradation rate of fibrin. In this study, we aimed to further improve the longevity of these PEG-fibrin gels such that they could be used for tissue engineering in vitro or in situ without the need for proteolysis inhibitors. It is well documented that increasing the salinity of fibrin precursor solutions affects the resulting gel morphology. Here, we investigated whether this altered morphology influences the fibrin degradation rate. Increasing the final sodium chloride (NaCl) concentration from 145 mM (physiologic level) to 250 mM resulted in fine, transparent high-salt (HS) fibrin gels that degrade 2-3 times slower than coarse, opaque physiologic-salt (PS) fibrin gels both in vitro (when treated with proteases and when seeded with amniotic fluid stem cells) and in vivo (when injected subcutaneously into mice). Increased salt concentrations did not affect the viability of encapsulated cells, the ability of encapsulated endothelial cells to form rudimentary capillary networks, or the ability of the gels to maintain induced pluripotent stem cells. Finally, when implanted subcutaneously, PS gels degraded completely within one week while HS gels remained stable and maintained viability of seeded dermal fibroblasts. To our knowledge, this is the simplest method reported for the fabrication of fibrin gels with tunable degradation properties and will be useful for implementing fibrin gels in a wide range of research and clinical applications.

Indexed as

Cell LineCross-Linking ReagentsFibrinFibrinogenHumansHuman Umbilical Vein Endothelial CellsHydrogelsInduced Pluripotent Stem CellsPolyethylene GlycolsSalinitySodium ChlorideSolventsStem Cell TransplantationSuccinimidesTissue EngineeringCross-Linking ReagentsFibrinFibrinogenHydrogelsN-hydroxysuccinimidePolyethylene GlycolsSodium ChlorideSolventsSuccinimides

Identifiers

PMID34010323
PMCPMC8133424
OpenAlexW3160196568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.